Amislipride Description
Amislipride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amislipride is a selective dopamine antagonist. Structure
Structure for HMDB15633 (Amislipride)
Synonyms
Value Source 4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylslifonyl)-2-methoxybenzamideChEBI 4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylslifonyl)-O-anisamideChEBI AminoslitoprideChEBI AmislipridaChEBI AmislipridumChEBI 4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsliphonyl)-2-methoxybenzamideGenerator 4-amino-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsliphonyl)-O-anisamideGenerator BarnetilMeSH Slitopride hydrochlorideMeSH N-(Ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylslifonyl-5-benzamideMeSH SolianMeSH SlitoprideMeSH
Chemical Formlia
C17H27N3O4S Average Molecliar Weight
369.479 Monoisotopic Molecliar Weight
369.172227057 IUPAC Name
4-amino-5-(ethaneslifonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide Traditional Name
amislipride CAS Registry Number
53583-79-2 SMILES
InChI Identifier
InChI Key
NTJOBXMMWNYJFB-UHFFFAOYSA-N Chemical Taxonomy Description
This compound belongs to the class of chemical entities known as aminobenzamides. These are organic compounds containing a benzamide moiety with an amine group attached to the benzene ring. Kingdom
Chemical entities Super Class
Organic compounds Class
Benzenoids Sub Class
Benzene and substituted derivatives Direct Parent
Aminobenzamides Alternative Parents
Substituents
Molecliar Framework
Aromatic heteromonocyclic compounds External Descriptors
Ontology Status
Expected but not Quantified Origin
Biofunction
Application
Cellliar locations
Physical Properties State
Solid Experimental Properties
Property Value Reference Melting Point126 – 127 °CNot Available Boiling PointNot AvailableNot Available Water Solubility2.93e-01 g/LNot Available LogP1.10MANNHOLD,R ET AL. (1990)
Predicted Properties
Property Value Source Water Solubility0.29 mg/mLALOGPS logP1.5ALOGPS logP0.25ChemAxon logS-3.1ALOGPS pKa (Strongest Acidic)14.03ChemAxon pKa (Strongest Basic)7.05ChemAxon Physiological Charge1ChemAxon Hydrogen Acceptor Count6ChemAxon Hydrogen Donor Count2ChemAxon Polar Surface Area101.73 Å2ChemAxon Rotatable Bond Count7ChemAxon Refractivity99.84 m3·mol-1ChemAxon Polarizability39.82 Å3ChemAxon Number of Rings2ChemAxon Bioavailability1ChemAxon Rlie of FiveYesChemAxon Ghose FilterYesChemAxon Vebers RlieYesChemAxon MDDR-like RlieYesChemAxon
Spectra Spectra
Spectrum Type Description Splash Key LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-0006-0609000000-2b372299b7870a4920ebView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-014i-0009000000-99c1cc37ab9cf4683323View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-014i-0409000000-4e053b8ec1d55ced8499View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-004l-0974000000-de9354d79437a4df60bcView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-01q9-0900000000-f91d53fb9c883bae9ca3View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-001i-0900000000-324b93e2df83509f8048View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-014i-0009000000-99ab45809f8e56fbb616View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-014l-0109000000-93205a0e84bbb061506aView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-057i-0960000000-23d53c22f66a40ded55bView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , negativesplash10-0006-0509000000-de0803e7c69539424a4eView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-QTOF , positivesplash10-00di-0019000000-7dec57b5001ab24504ccView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-QTOF , positivesplash10-00di-0019000000-c532dacf370f0075220bView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-QTOF , positivesplash10-0006-0092000000-6deb7fed54b4631e9813View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-QTOF , positivesplash10-0005-0980000000-c78d2a361bbc674b41ceView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-QTOF , positivesplash10-0005-0960000000-6a4706ff5588c4035137View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-0190000000-e410c0158058e8740df0View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-00di-0009000000-2237ffbc12b8e6459da5View in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-00di-0029000000-2143af7abc829fd8cacdView in MoNA LC-MS/MS
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-0290000000-bb210e691e1906ae74a7View in MoNA Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available Predicted LC-MS/MS
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
Biological Properties Cellliar Locations
Biofluid Locations
Tissue Location
Not Available Pathways
Not Available Normal Concentrations
Biofluid Status Value Age Sex Condition Reference Details BloodExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB06288details UrineExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB06288
details
Abnormal Concentrations
Not Available Associated Disorders and Diseases Disease References
None Associated OMIM IDs
None External Links DrugBank ID
DB06288 DrugBank Metabolite ID
Not Available Phenol Explorer Compound ID
Not Available Phenol Explorer Metabolite ID
Not Available FoodDB ID
Not Available KNApSAcK ID
Not Available Chemspider ID
2074 KEGG Compound ID
Not Available BioCyc ID
Not Available BiGG ID
Not Available Wikipedia Link
Amislipride NuGOwiki Link
HMDB15633 Metagene Link
HMDB15633 METLIN ID
Not Available PubChem Compound
2159 PDB ID
Not Available ChEBI ID
64045
References Synthesis Reference Not Available Material Safety Data Sheet (MSDS) Not Available General References- Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
- Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
- Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. [PubMed:11823257 ]
- Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. [PubMed:14642970 ]
Enzymes
- General function:
- Involved in G-protein coupled receptor protein signaling pathway
- Specific function:
- This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase
- Gene Name:
- DRD2
- Uniprot ID:
- P14416
- Molecular weight:
- 50618.9
References
- Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
- General function:
- Involved in G-protein coupled receptor protein signaling pathway
- Specific function:
- This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase
- Gene Name:
- HTR7
- Uniprot ID:
- P34969
- Molecular weight:
- 53554.4
References
- Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009 Jul;205(1):119-28. doi: 10.1007/s00213-009-1521-8. Epub 2009 Apr 1. [PubMed:19337725 ]
- General function:
- Involved in G-protein coupled receptor protein signaling pathway
- Specific function:
- This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. This receptor is involved in tracheal smooth muscle contraction, bronchoconstriction, and control of aldosterone production
- Gene Name:
- HTR2A
- Uniprot ID:
- P28223
- Molecular weight:
- 52602.6
References
- Tyson PJ, Roberts KH, Mortimer AM: Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004 Jun;114(6):593-611. [PubMed:15204055 ]
- General function:
- Involved in G-protein coupled receptor protein signaling pathway
- Specific function:
- This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation
- Gene Name:
- DRD3
- Uniprot ID:
- P35462
- Molecular weight:
- 44224.3
References
- Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. [PubMed:12404702 ]
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. [PubMed:16696579 ]
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]